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I. Overview 
Proton-pump inhibitors (PPIs) are group of drugs having long-lasting reduction of gastric 
acid production. PPIs are the most effective inhibitors of acid secretion (The Health 
Strategies Consultancy LLC, 2005). There is similar pharmaceutical group called 
histamine2 (H2)-receptor antagonists in increasing intragastric pH. Comparing these two 
groups, PPIs are proven to be more effective but the effectiveness depends on the 
individual PPI agents. The individual agents of PPIs are for example esomeprazole, 
pantoprazole, illaprazole, dexlansoprazole, lansoprazole, rabeprazole, and omeprazole. 
The majority of PPIs are benzimidazole derivatives but research found that 
imidazopyridine derivatives may be more effective for treatment purposes (Sachs, Shin, 
and Howden, 2006). 
 
 
 
 
 
 
   
Proton-pump inhibitors (“Wikipedia: Proton Pump Inhibitors”) 
 
PPIs are used as treatment for acid-related diseases including gastroesophageal reflux 
diseases (GERD) and peptic ulcer disease. GERD is a symptom of acid reflux whereby 
gastric acid comes out from stomach to the oesophagus (De Vault and Castell, 1999) 
whereas peptic ulcer is a disease whereby the lining of the stomach and the duodenum is 
sore because of the lack of proportion of gastric acid in the stomach (WebMD). They are 
also used as treatments against Barrett’s esophagus and Zollinger-Ellison syndrome 
(Sachs, 1997). Barrett’s esophagus is a disease whereby the lining in the esophagus is 
replaced with the lining that is similar to that in the intestine. It is known to increase 
people’s vulnerability to cancer (NDDIC, 2013). Zollinger-Ellison is caused by the 
increase in the production of gastrin. Gastrin is a peptide hormone that stimulates the 
Imidazopyridine 
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secretion of gastric acid in the stomach (Medline Plus, 2012). Besides its effectiveness in 
treating diseases, PPIs also inhibit the growth of Helicobacter pylori which causes peptic 
ulcer diseases. 
  
 
 
 
 
 
   Helicobacter pylori (Bioweb) 
H.pylori damages the coating lining of stomach and duodenum causing the gastric acid to 
reach the inner lining and irritate them (NDDIC, 2013).When PPIs are combined with 
antibiotics, it has been shown medically that this eradicates the growth of bacterium. 
Some PPI agents like lansoprazole, rabeprazole, and omeprazole have similar 
characteristics. These agents are used mainly to inhibit gastric acid secretion. They are 
mainly targeting the gastric acid pump, H+, K+—adenosine triphosphatase (ATPase) in 
the canalicular membrane of the parietal cell (Horn J, 2000).  
 
 
 
 
 
 
 
 
 
 
 
 
 
   Canalicular membrane (Richard, 2012) 
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The rates of absorption of omeprazole and lansoprazole decrease when they are taken 
together with food (Astrazeneca pty ltd, 2005).  
In general, PPIs may lead to increased risk of development of food allergies by 
suppressing acid-mediated breakdown of proteins. Proteins that are not digested then 
travel into the digestive system, leading to sensitization to a range of food or drugs 
(Diesner and Knittelflder, 2008). Risk of developing drug hypersensitivity may occur. 
Consumption of acid-suppressive drugs during pregnancy may also cause childhood 
asthma (“Wikipedia: Proton Pump Inhibitor”). The effects of PPIs may be categorized 
into two types, namely short-term effects and long-term effects. Short-term effects may 
include headache, nausea, diarrhea, abdominal pain, fatigue, and dizziness (Rossi, 2006). 
Infrequent harmful effects include rash, itch, flatulence, constipation, anxiety, and 
depression.  PPIs may also cause erythema multiforme, pancreatitis, Stevens-Johnson 
syndrome, thrombocytopenia, hyperprolactinaemia and acute interstitial nephritis in some 
rare cases (Simpson et al., 2006). Other effects that may be caused by the PPIs are 
community-acquired pneumonia (Eom et al., 2010), skin ageing (Namazi and Jowkar, 
2010), transmucosal gastric leak (Murray and Gabello, 2009), myopathies, and 
rhabdomyolysis (Clark and Strandell, 2006). 
 
Long-term consumption of PPIs may lead to several side effects. The common one is the 
increased risk of fractures of the hip, wrist, and spine (Sharara et al., 2012). This is 
because gastric acid is used by food particles to dissociate iron salts into complexes that 
will be absorbed by the body as a source of iron (Annibale, Capurso, and Delle Fave, 
2003). Gastric acid is also needed to release vitamin B12 from food particles (Rossi, 
2006). Since gastric acid is reduced, iron and vitamin B12 absorption are also reduced. 
The bones can then become more fragile as homocysteine (non-protein α amino acid) 
increases (Abrahamsen and Vestergaard, 2013). Other side-effects are occurrence of 
anemia, heart arrhythmias, and Fundic gland polyps (“Wikipedia: Proton Pump 
Inhibitor”). Zinc absorption interference and gastric symptoms built up can also be 
caused by long-term use of PPIs (Farrell, 2011). Rare harmful effects include acute 
interstitial nephritis leading to chronic kidney disease and renal disease (Sierra and 
Suarez, 2007).  
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One common and harmful effect of proton pump inhibitor is diarrhea. PPIs can cause a 
diarrhea since PPIs inhibit gastric acid secretion. Bacteria such as Salmonella can then 
colonize the gut causing enterocolitis accompanied by diarrhea or loose bowels (Garcia et 
al., 2007). Shimura et al investigated the occurrence of diarrhea caused by three different 
PPIs namely lansoprazole, rabeprazole, and omeprazole. The investigation was conducted 
since there is an increase in the usage of PPIs for treating patients with GERD. Targets 
for this investigation were outpatients older than 20 years old who were taking a PPI for 
more than a month. They were then told to record the occurrences of diarrhea and loose 
bowel for a month daily. The result would then be categorized through diarrhea-related 
QOL impairment and Bristol Stool Scale Form. The former was categorized into 5 grades 
from embarrassment to the inability to perform daily activities, while the latter was an aid 
to categorize human faeces into seven categories. χ2-test will then be used to determine 
whether there is correlation among the three different PPI agents. Results found that there 
was no significant difference for the incidence of diarrhea among the 3 types of PPIs and 
there was no link between diarrhea and the length and dosage of PPI administration. The 
rate of occurrence of diarrhea in all patients was as low as 3.5% (Shimura et al., 2012).  
 
II. Specific agent of PPIs (Omeprazole) 
Omeprazole is one of the proton-pump inhibitors used to treat diseases like dyspepsia, 
peptic ulcer, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-
Ellison syndrome. The chemical name of omeprazole is 6-methoxyl-2-((4-methoxy-3,5-
dimethylpyridin-2-yl) methylsulfinyl)-1 H-benzo[d]imidazole.  
 
 
 
 
 
 
Omeprazole (“wikipedia: Omeprazole”) 
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Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and thus it 
is able to exist as either the (S)-(-) or (R)-(+) enantiomers. The major difference is that S-
enantiomers metabolize more slowly than the R-enantiomers (Vyas et al., 2011). 
Omeprazole is a racemate meaning that it exists as equal mixture of the two (“Wikipedia: 
Omeprazole”).  
 
 
 
 
 
 
Enantiomers (Vyas et al., 2011) 
Both of the enantiomers will then be converted to achiral products like sulfenic acid and 
sulfonamide configurations in the acidic conditions of the canaliculi of parietal cells. 
These achiral products will then react with a cysteine group in H+/K+ ATPase which 
leads to the ability of the parietal cells to produce gastric acid (“Wikipedia: 
Omeprazole”).  
 
 
 
 
 
 
 
 
Conversion of enantiomers (Wikipedia) 
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Omeprazole works by inhibiting parietal cell H+/K+ ATPase, the gastric “proton pump”. 
After omeprazole is released from coating, it is converted into active sulfonamide form in 
the acidic environment (MedicineNet, 2009). This active sulfonamide form is then form 
covalent bond to cysteine residues to release proton pumps. These bonds result in a 
complete inhibition of gastric acid production and this inhibition will last until new 
proton pump molecules are synthesized (Madanick, 2011). In acidic environment, 
omeprazole breaks down and this can cause omeprazole to be broken down in the 
stomach before reaching the target. Thus, omeprazole is produced as capsule containing 
enteric-coated granules (Bandolier, 2003). Interaction between omeprazole and other 
kinds of drugs can result in the inhibition of metabolism of drugs for example omeprazole 
will inhibit the metabolism of clarithromycin, benzodiazepines, phenytoin, and warfarin 
(MediciNet, 2009). Since omeprazole and clarithromycin inhibit the metabolism of the 
other, it can be used as a short-term therapy for H. pylori eradication (Bandolier, 2003). 
III. Specific effects of Omeprazole 
A. Effect of Omeprazole on human arteries. 
Examination on the effect of using H+/K+ -ATPase inhibitors on human internal 
mammary and radial arteries was conducted and it was found that Omeprazole causes 
concentration-dependent, reversible, and reproducible relaxations of arteries which were 
contracted with phenyilephrine, histamine, ouabain, amd K+ free solution before the 
experiment was conducted. Potassium ions play essential roles in regulating cell volume, 
vascular reactivity and acid-base balance. The proton pump actively takes up K+ in 
exchange of H+ that flows out, (Naseri and Yenisehirli, 2005) regulating the intracellular 
pH and K+. Through this regulation, the proton pump is responsible for the acid secretion. 
(Sachs et al., 1976). 
 
Experiment was conducted using internal mammary and radial artery segment from 19 
patients undergoing coronary artery by-pass grafting. Solution was then bubbled with 
95% O2 and 5% CO2 to prevent tissue ischemia. Before the experiment, Omeprazole was 
dissolved in methanol. The concentrations producing 50% of maximum contraction and 
50% of maximum relaxation were then calculated using non-linear regression analysis. 
Findings showed that Omeprazole had no effect on the basal tone of isolated human 
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arterial rings. However, they are able to relax all arteries that were contracted with 
phenylephrine, histamine, high K+, ouabain, and K+ free solution before the experiment 
was conducted. Omeprazole produced concentration-dependent relaxation of the rings 
that were contracted with either phenylephrine or histamine. It also produced 
concentration-dependent relaxations in arteries that were contracted with K+-free 
solution. The ability of Omeprazole as a relaxant was also found to be independent from 
anatomical location or structure of the arteries (Naseri and Yenisehirli, 2005). 
 
B. Effect of Omeprazole in children. 
Proton pump inhibitors (PPIs) are used to treat gastric hypersecretory diseases in children 
although currently there is no established dosage for children. Besides, they can also be 
used to treat ulcers, gastro-esophageal reflux disorders (GERD) (Marchetti, Gerarduzzi, 
and Ventura, 2003), Barrett’s esophagus, pseudo-Zollinger-Ellison syndrome (De 
Giacomo et al., 1990). These drugs are also useful in increasing gastric pH before and 
after surgery (Kaufmann et al., 2002) and improving fat absorption in children with cystic 
fibrosis (Francisco et al., 2002). Cystic fibrosis is a disorder that is passed genetically 
which affects lungs, pancreas, liver, and intestine. It causes sodium and chloride to be 
transported abnormally and thus results in the thickening of secretions. Study was done to 
investigate the effectiveness of omeprazole in treating GERD in children age 12-19. 32 
children were suffering from severe esophagitis and were given omeprazole and 
ranitidine at advisable dosage. Result showed that health of children treated with 
omeprazole improved tremendously although for severe GERD, high-dose ranitidine was 
as effective as omeprazole (Marchetti, Gerarduzzi, and Ventura, 2003). 
Gastric ulcer in children can be caused by H. Pylori infection and PPIs like omeprazole 
can be used to eliminate H. pylori (“Wikipedia: Omeprazole”). Investigation was done by 
Kato et al. to see the effectiveness of omeprazole in treating ulcers. 22 children age 8-16 
was given omeprazole to eliminate H. pylori. Some children were given omeprazole and 
amoxicillin and some were given omeprazole, amoxicillin, and clarithromycin. Results 
showed that ulcers were treated completely. The percentage of elimination of H. pylori is 
higher in those treated with triple drugs therapy than that treated with dual drugs therapy 
(Kato et al., 1997). 
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Treatment with omeprazole may result in temporary increase in liver function studies 
without reports of hepatitis (Romero-Gomez et al,. 1999). Patients suffering from 
Zollinger-Ellison syndrome who are undergoing long-term treatment with omeprazole 
can experience a reduction in serum vitamin B12 levels (Termanini et al., 1998). 
IV.  Conclusion 
The proton-pump inhibitors (PPIs) are drugs used mainly to inhibit gastric acid 
production by targeting the gastric acid pump, H+, K+, adenosine triphosphatase 
(ATPase) in the canalicular membrane of the parietal cell (Horn J, 2000). Many PPIs 
agent like omeprazole, lansoprazole, rabeprazole, esomeprazole are available to public 
due to its effectiveness in suppressing gastric acid secretion (Sachs, Shin, and Howden, 
2006). These PPI agents are also able to treat harmful diseases, with the common ones 
being GERD and stomach ulcers. It inhibits the growth of Helicobacter pylori in the 
latter (NDDIC, 2013). In general, PPIs are able to cause several side-effects ranging from 
the less harmful to more adverse despite their effectiveness for treatment of acid-related 
diseases. In Japan, an investigation is conducted to analyze the occurrence of diarrhea in 
patients undergoing treatment for GERD. Diarrhea is mentioned to be one of the harmful 
side-effects of using PPIs. Few different PPI agents are given to patients and results show 
that the rate of occurrence of diarrhea remains low, showing that it is well-tolerated 
(Shimura et al., 2012). 
 
Omeprazole, an agent of PPI, exists as S- and R- enantiomers with equal probability 
(Vyas et al., 2011).  In order to reach the intended location without being digested, 
omeprazole is produced as capsule containing enteric-coated granules (Bandolier, 2003). 
Not only that it is effective in treating patients with GERD, its interaction with another 
drug can eradicate H. pylori which poses danger to human’s health (Wikipedia article). 
Omeprazole also has other uses. It is able to relax human arteries (Naseri and Yenisehirli, 
2005) and treat children with GERD, while improving fat absorption in children with 
cystic fibrosis (Francisco et al., 2002). It can also increase intragastric pH before and 
after surgery (Kaufmann et al., 2002) and eliminate H. pylori in children suffering from 
stomach ulcers (“Wikipedia: Omeprazole”). 
 
9 
 
V. References 
Abrahamsen B, Vestergaard P. Proton pump inhibitor use and fracture risk - effect modification 
by histamine H1 receptor blockade. Observational case-control study using National 
Prescription Data. Bone. 2013;57:269-271 
 
Annibale B, Capurso G, Delle Fave G. The stomach and iron deficiency anaemia: a forgotten 
link. Dig Liver Dis.2003;35:288–295 
 
AstraZeneca Pty ltd. 2005 
 
Bandolier. Proton pump inhibitors and clostridium difficile. 2003 
 
Bioweb. Taken from: http://bioweb.uwlax.edu/bio203/s2008/pluym_evan/ 
 
Clark DW, Strandell J. Myopathy including polymyositis: a likely class adverse effect of proton 
pump inhibitors? European Journal of Clinical Pharmacology. 2006;62:473–479 
 
De Giacomo C, Fiocca Rm Villani L, Licardi G, Scotta MS, Solcia E. Omeprazole treatment of 
severe peptic disease associated with antral G cell hyperfunction and 
hyperpepsinogenemia I in an infant. J Pediatr. 1990;117:989-993 
 
DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of 
gastroesophageal reflux disease. The Practice Parameters Committee of the American 
College of Gastroenterology. Am J Gastroenterol. 2004;94(6):1434–1442 
 
Diesner SC, Knittelfelder R. Dose-dependent food allergy induction against ovalbumin under 
acid-suppression: A murine food allergy model. Immunology Letters. 2008;121:45-51 
 
Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk 
of pneumonia: A systemic review and meta-analysis. Canadian Medical Association 
Journal. 2010;183:310–319. 
 
Farrell. Proton Pump Inhibitors Interfere with Zinc Absorption and Zinc Body Stores. 
Gastroenterology Research. 2011 
 
Francisco MP, Wagner MH, Sherman JM, Theriaque D, Bowser E, Novak DA.. Ranitidine and 
omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with 
cystic fibrosis. J Pediatr Gastroenterol Nutr.  2002; 35:79-83 
 
10 
 
Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-supressing drugs and the risk of  
bacterial gastroenteritis. Clin Gastroennterol Hepatol. 2007;5:1418-1423 
Horn J. The Proton-Pump Inhibitors: Similarities and Differences. Clinical therapeutics. 
2000;22:266-280 
 
Kato S, Takeyama J, Ebina K, Naganuma H. Omeprazole-based dual and triple regimens for 
Helicobacter pylori eradication in children. Pediatrics. 1997;100:e3 
 
Kaufmann SS, Lyden ER, Brown CR, Davis CK, Andersen DA, Olsen KM, et al. Omeprazole 
therapy in pediatric patients after liver and intestinal transplantation. J Pediatr 
Gastroenterol Nutr. 2002;34:194-198 
 
Madanick RD. Proton pump inhibitor side effects and drug interactions: much ado about 
nothing? Cleve Clin J Med. 2011;78(1):39–49. 
Marchetti F, Gerarduzzi T, Ventura A. Proton pump inhibitors in children: a review. Digestive 
and liver disease. 2003;35:738-746 
MediciNet. What causes ulcers? 2009 
 
Medline Plus. Zollinger- Ellison syndrome. National Institutes of Health. 2012. 
 
Murray LJ, Gabello M. Transmucosal gastric leak induced by proton pump inhibitors. Digestive 
Diseases and Sciences. 2009;54(7):1408–1417 
 
Namazi MR, Jowkar F. Can Proton Pump Inhibitors Accentuate Skin Aging? Archives of 
Medical Research. 2010;41(2):147–148 
 
Naseri E, Yenisehirli A. Proton pump inhibitors omeprazole and lansoprazole induce relaxation 
of isolated human arteries. European Journal of Pharmacology. 2006;531:226-231 
 
National Digestive Diseases Information Clearinghouse (NDDIC). Barrett’s Esophagus. National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2013 
 
National Digestive Diseases Information Clearinghouse (NDDIC). H. pylori and peptic ulcers. 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2013 
 
Richard. Cholestasis: Basolateral membrane transport and intracellular transport. 2012. Taken 
from http://www.depressionofspirits.com/cholestasis-basolateral-membrane-transport-
and-intracellular-transport-238.html 
 
11 
 
Romero-Gomez M, Otero MA, Suarez-Garcia E, Garcia Diaz E, Fobelo MJ, Castro-Fernandez 
M. Acute hepatitis related to omeprazole. Am J Gastroenterol. 1999;94:1119-1120 
 
Rossi S, editor. Australian Medicines Handbook. 2006 
 
Sachs G. Proton pump inhibitors and acid related diseases. Pharmacotherapy. 1997;17:22-37 
 
Sachs G, Chang HH, Rabon E, Schackman R, Lewin M, Saccomani G. A nonelectrogenic H+ 
pump in plasma membranes of hog stomach. J Biol Chem. 1976;251:7690-7698 
 
Sachs G, Shin JM, Howden CW. Review article: The clinical pharmacology of proton pump 
inhibitors. Alimentary Pharmacology and Therapeutics.2006;23:2-8 
 
Sharara AI, El-Halabi MM, Ghait OA, Habib RH, Mansour NM, Malli A, El Hajj-Fuleihan G. 
Proton Pump inhibitors have no measurable effect on calcium and bone metabolism in 
healthy young males: A prospective matched controlled Study. Metabolism. 
2012;62(4):518–526 
 
Shimura S, Hamamoto N, Yoshino N, Kushiyama Y, Fujishiro H, Komazawa Y, et al. Diarrhea 
caused by proton pump inhibitor administration: Comparisons Among Lansoprazole, 
Rabeprazole, and Omeprazole. Current Therapeutic Research. 2012;73:112-120 
Sierra F, Suarez M. Systematic review: Proton pump inhibitor-associated acute interstitial 
nephritis. Alimentary Pharmacology & Therapeutics. 2007;26(4):545–555 
 
Simpson IJ, Marshall MR, Pilmore H, Manley P, Williams L,  Thein HLA, Voss D. Proton pump 
inhibitors and acute interstitial nephritis: Report and analysis of 15 cases. Nephrology. 
2006;11 
 
Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid 
suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison 
syndrome. Am J Med. 1998;104:422-430 
 
The Health Strategies Consultancy LLC. Follow The Pill: Understanding the U.S. Commercial 
Pharmaceutical Supply Chain. The Kaiser Family Foundation. 2005 
 
Vyas S, Patel A, Ladva KD, Joshi H S, Bapodra AH. Development and validation of a stability 
indicating method for the enantio selective estimation of omeprazole enantiomers in the 
enteric-coated formulations by high-performance liquid chromatography. J Pharm Bioall 
Sci. 2011;3:310-314 
 
12 
 
WebMD. Peptic ulcer disease. Taken from http://www.webmd.com/digestive-
disorders/digestive-diseases-peptic-ulcer-disease 
 
Wikipedia Article. Proton pump inhibitor. Taken from http://en.wikipedia.org/wiki/Proton-
pump_inhibitor. 
 
Wikipedia Article. Omeprazole. Taken from http://en.wikipedia.org/wiki/Omeprazole 
